Related Experiment Video
Updated: Mar 13, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
986
Antidepressants and colorectal cancer: A population-based nested case-control study.
Hsiu-Chiung Lee1, Wei-Che Chiu2, Tsu-Nai Wang3
1Tsaotun Psychiatric Center, Ministry of Health and Welfare, Nantou, Taiwan.
Journal of Affective Disorders
|October 17, 2016
Summary
Antidepressant use was examined for colorectal cancer risk. Most antidepressants showed no increased risk, but monoamine oxidase inhibitors were linked to higher incidence. Mirtazapine may offer a protective effect, though further research is needed.
Area of Science:
- Oncology
- Pharmacology
- Epidemiology
Background:
- Serotonin's dual role in tumor growth suggests a link to colorectal cancer.
- Antidepressant medications, which affect serotonin, warrant investigation for their impact on colorectal cancer risk.
Purpose of the Study:
- To investigate the epidemiological association between antidepressant use and colorectal cancer incidence.
- To assess risks associated with specific classes of antidepressants, including genotoxic agents.
Main Methods:
- A population-based case-control study was conducted using Taiwan's National Health Insurance Research Database.
- Data included 49,342 colorectal cancer cases and 240,985 controls from 1997-2008.
- Conditional logistic regression analyses were performed to determine associations.
Main Results:
- Selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and serotonin antagonist and reuptake inhibitors were not associated with increased colorectal cancer risk.
- Monoamine oxidase inhibitors (MAOIs) showed an increased incidence of colorectal cancer (adjusted OR=1.22).
- Higher cumulative mirtazapine doses were associated with decreased colorectal cancer incidence (adjusted OR=0.39), though sample size limits conclusions.
Conclusions:
- Contemporary antidepressants like SSRIs and SNRIs, and older agents like TCAs, do not elevate colorectal cancer incidence.
- Monoamine oxidase inhibitors may be associated with an increased risk of colorectal cancer.
- Mirtazapine's potential protective effect requires further investigation due to limited sample size.
More Related Videos
Related Concept Videos
01:25Antidepressant Drugs: Overview
1.9K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.9K
01:23Antidepressant Drugs: MAOIs and Other Agents
1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.2K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.2K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.9K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.9K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
832
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
832
01:21Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K